Adagene Inc

NASDAQ ADAG

Data sourced from

and

Daily

Download Data

Adagene Inc Enterprise Value to EBITDA (EV/EBITDA) on June 03, 2024: -1.04

Adagene Inc Enterprise Value to EBITDA (EV/EBITDA) is -1.04 on June 03, 2024, a NA change year over year. The EV/EBITDA ratio compares a company's enterprise value to its EBITDA. It provides insight into the company's valuation relative to its earnings and is commonly used in comparing the relative value of different companies within an industry. A lower ratio suggests a potentially more favorable valuation.

Adagene Inc 52-week high Enterprise Value to EBITDA (EV/EBITDA) is 0.80 on August 18, 2023, which is 176.51% above the current Enterprise Value to EBITDA (EV/EBITDA).
Adagene Inc 52-week low Enterprise Value to EBITDA (EV/EBITDA) is -2.32 on January 25, 2024, which is -123.58% below the current Enterprise Value to EBITDA (EV/EBITDA).
Adagene Inc average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is -0.11.

NASDAQ: ADAG

Adagene Inc

CEO	Dr. Peter P. Luo Ph.D.
IPO Date	Feb. 9, 2021
Location	China
Headquarters	Building C14, Suzhou, China, 215123
Employees	174
Sector	Healthcare
Industry	Biotechnology

Description

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Key trends